eClinical Technology and Industy News

Elucida Oncology Submits IND Application for ELU-001 for the Treatment of Cancers Overexpressing Folate-Receptor Alpha

Excerpt from the Press Release:

MONMOUTH JUNCTION, N.J., July 19, 2021 (GLOBE NEWSWIRE) — Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial of ELU-001, the company’s C’Dot Drug Conjugate (CDC) being developed as a treatment for patients with advanced, recurrent, or refractory cancers overexpressing folate-receptor alpha (FRα).

“This is a tremendous accomplishment for our team, and a great step forward in developing newer, potentially more effective, and better tolerated therapies for patients with cancer. This first C’Dot-Drug-Conjugate, using the innovative C’Dot platform, could pave the way to an entirely new frontier in precision cancer therapy,” stated Geno Germano, President and CEO of Elucida Oncology.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?